MX2018006729A - Tratamiento de la degeneracion de la retina mediante el uso de celulas progenitoras. - Google Patents

Tratamiento de la degeneracion de la retina mediante el uso de celulas progenitoras.

Info

Publication number
MX2018006729A
MX2018006729A MX2018006729A MX2018006729A MX2018006729A MX 2018006729 A MX2018006729 A MX 2018006729A MX 2018006729 A MX2018006729 A MX 2018006729A MX 2018006729 A MX2018006729 A MX 2018006729A MX 2018006729 A MX2018006729 A MX 2018006729A
Authority
MX
Mexico
Prior art keywords
cells
progenitor cells
treatment
retinal degeneration
retinal
Prior art date
Application number
MX2018006729A
Other languages
English (en)
Inventor
Sophia DEJNEKA Nadine
Cao Jing
Harris Ian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2018006729A publication Critical patent/MX2018006729A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se describen métodos y composiciones para tratar y reducir la degeneración de la retina con el use de células progenitoras y medio acondicionado a partir de las células progenitoras, tales como células derivadas del posparto. Se describen, además, factores genéticos y receptores expresados por células progenitoras que ayudan en la protección de células retínales y la inhibición de la apoptosis de células retínales, tales como células fotorreceptoras.
MX2018006729A 2015-12-04 2016-12-01 Tratamiento de la degeneracion de la retina mediante el uso de celulas progenitoras. MX2018006729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263463P 2015-12-04 2015-12-04
PCT/US2016/064336 WO2017095991A1 (en) 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells

Publications (1)

Publication Number Publication Date
MX2018006729A true MX2018006729A (es) 2018-11-09

Family

ID=58797699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006729A MX2018006729A (es) 2015-12-04 2016-12-01 Tratamiento de la degeneracion de la retina mediante el uso de celulas progenitoras.

Country Status (15)

Country Link
US (1) US20170157179A1 (es)
EP (1) EP3384009A4 (es)
JP (1) JP2019501888A (es)
KR (1) KR20180088713A (es)
CN (1) CN108291199A (es)
AR (1) AR106913A1 (es)
AU (1) AU2016365312A1 (es)
BR (1) BR112018011278A2 (es)
CA (1) CA3007198A1 (es)
MX (1) MX2018006729A (es)
PH (1) PH12018501045A1 (es)
RU (1) RU2018122461A (es)
SG (1) SG11201803781XA (es)
TW (1) TW201729819A (es)
WO (1) WO2017095991A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
KR102224115B1 (ko) 2020-01-10 2021-03-09 경북대학교병원 3차원 바이오프린팅 기술을 이용한 망막 세포 배양용 구조체 및 이의 활용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001855A (en) * 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
PL207175B1 (pl) * 2001-08-01 2010-11-30 Merck Patent Gmbh Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu
US7560276B2 (en) * 2003-06-27 2009-07-14 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
AU2008321386B2 (en) * 2007-11-15 2014-10-23 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8
EP2707036A4 (en) * 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
US20150150996A1 (en) * 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
BR112017012581A2 (pt) * 2014-12-16 2017-12-26 Janssen Biotech Inc tratamento de degeneração da retina com o uso de células progenitoras

Also Published As

Publication number Publication date
BR112018011278A2 (pt) 2018-11-21
AU2016365312A1 (en) 2018-05-24
SG11201803781XA (en) 2018-06-28
EP3384009A1 (en) 2018-10-10
EP3384009A4 (en) 2019-06-12
US20170157179A1 (en) 2017-06-08
CA3007198A1 (en) 2017-06-08
AR106913A1 (es) 2018-02-28
WO2017095991A1 (en) 2017-06-08
TW201729819A (zh) 2017-09-01
RU2018122461A (ru) 2020-01-13
CN108291199A (zh) 2018-07-17
KR20180088713A (ko) 2018-08-06
JP2019501888A (ja) 2019-01-24
PH12018501045A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
AU2019268063A1 (en) Compositions for modulating sod-1 expression
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
GB2541571A (en) Pharmaceutical compositions
EP3134120A4 (en) Compositions and methods for treating cytokine-related disorders
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IL251616B (en) Methods and compounds for the treatment and prevention of muscle mass loss
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EP3186269A4 (en) Compositions, methods and kits for treating complement related disorders
PH12017500602A1 (en) Methods for treating ocular conditions
EP3442554A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12018501045A1 (en) Treatment of retinal degeneration using progenitor cells
MX2017011619A (es) Uso de fracciones aisladas de goma almáciga para el tratamiento de la neuropatía óptica.
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use
EP3205717A4 (en) Method for proliferating neural progenitor cells and composition for treating nerve disorders containing proliferated neural progenitor cells